logo-loader
viewTyraTech, Inc.

Fresh start for Tyratech with new strategic focus on animal health

Bruno Jactel, chief executive of Tyratech Inc. (LON:TYR LON:TYRU) chats to Proactive's Andrew Scott about the proposed sale of Vamousse to Alliance Pharma plc (AIM: APH).

It's for an initial cash consideration of $13mln with Tyratech potentially being entitled to further performance-based payments of up to $4.5 million.

Jactel also outlines their new strategic focus on animal health and the plans they've got to maximise opportunities in what's a $6bln market.

Quick facts: TyraTech, Inc.

Price: - -

AIM:TYR
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

RM Secured Direct Lending to maintain dividend as it manages existing...

RM Secured Direct Lending PLC's (LON:RMDL) Pietro Nicholls talks Proactive London's Andrew Scott through an update they've issued with regards to the ongoing market uncertainty relating to the pandemic. He says the global effects of the spread of the new virus have significantly impacted both...

1 hour, 12 minutes ago

2 min read